Your browser doesn't support javascript.
loading
Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum.
Saad, Fred; Canil, Christina; Finelli, Antonio; Hotte, Sebastien J; Malone, Shawn; Shayegan, Bobby; So, Alan I; Aaron, Lorne; Basappa, Naveen S; Conter, Henry J; Danielson, Brita; Gotto, Geoffrey; Hamilton, Robert J; Izard, Jason P; Kapoor, Anil; Kolinsky, Michael; Lalani, Aly-Khan A; Lattouf, Jean-Baptiste; Morash, Christopher; Morgan, Scott C; Niazi, Tamim; Noonan, Krista L; Ong, Michael; Rendon, Ricardo A; Sehdev, Sandeep; Hew, Huong; Park-Wyllie, Laura; Chi, Kim N.
Afiliación
  • Saad F; Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal, QC, Canada.
  • Canil C; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
  • Finelli A; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Hotte SJ; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
  • Malone S; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
  • Shayegan B; St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
  • So AI; Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.
  • Aaron L; Service d-Urologie and Centre de la Prostate, Longueuil, QC, Canada.
  • Basappa NS; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
  • Conter HJ; William Osler Health System, University of Western Ontario, Brampton, ON, Canada.
  • Danielson B; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
  • Gotto G; Southern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada.
  • Hamilton RJ; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Izard JP; Kingston Health Sciences Centre, Queen's University, Kingston, ON, Canada.
  • Kapoor A; St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
  • Kolinsky M; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
  • Lalani AA; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
  • Lattouf JB; Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal, QC, Canada.
  • Morash C; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
  • Morgan SC; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
  • Niazi T; Jewish General Hospital, McGill University, Montreal, QC, Canada.
  • Noonan KL; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada.
  • Ong M; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
  • Rendon RA; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
  • Sehdev S; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
  • Hew H; Medical Affairs, Janssen Inc, Toronto, ON, Canada.
  • Park-Wyllie L; Medical Affairs, Janssen Inc, Toronto, ON, Canada.
  • Chi KN; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada.
Can Urol Assoc J ; 14(4): E137-E149, 2020 Apr.
Article en En | MEDLINE | ID: mdl-31702544
ABSTRACT

INTRODUCTION:

The management of advanced prostate cancer (PCa) continues to evolve with the emergence of new diagnostic and therapeutic strategies. As a result, there are multiple areas in this landscape with a lack of high-level evidence to guide practice. Consensus initiatives are an approach to establishing practice guidance in areas where evidence is unclear. We conducted a Canadian-based consensus forum to address key controversial areas in the management of advanced PCa.

METHODS:

As part of a modified Delphi process, a core scientific group of PCa physicians (n=8) identified controversial areas for discussion and developed an initial set of questions, which were then reviewed and finalized with a larger group of 29 multidisciplinary PCa specialists. The main areas of focus were non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC), metastatic castration-resistant prostate cancer (mCRPC), oligometastatic prostate cancer, genetic testing in prostate cancer, and imaging in advanced prostate cancer. The predetermined threshold for consensus was set at 74% (agreement from 20 of 27 participating physicians).

RESULTS:

Consensus participants included uro-oncologists (n=13), medical oncologists (n=10), and radiation oncologists (n=4). Of the 64 questions, consensus was reached in 30 questions (n=5 unanimously). Consensus was more common for questions related to biochemical recurrence, sequencing of therapies, and mCRPC.

CONCLUSIONS:

A Canadian consensus forum in PCa identified areas of agreement in nearly 50% of questions discussed. Areas of variability may represent opportunities for further research, education, and sharing of best practices. These findings reinforce the value of multidisciplinary consensus initiatives to optimize patient care.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: Can Urol Assoc J Año: 2020 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: Can Urol Assoc J Año: 2020 Tipo del documento: Article País de afiliación: Canadá